PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial

Clinical trial NCT04814043 · UNKNOWN

Trial details

NCT number: NCT04814043
Sponsor: Sun Yat-sen University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2021-04-20
Primary completion: 2022-12-30
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.